Table 1.

MIC distributions of novel compounds and comparator agents against 200 P. aeruginosa isolates, by resistance phenotype

Resistance phenotype (MIC; n)	Agent	No. of isolates (cumulative %) inhibited at MIC (μg/ml) of:
		≤0.5	1	2	4	8	16	32	64	≥128
R-IMI (≥16 μg/ml; 84)	RX-P763	2 (2)	5 (8)	33 (48)	38 (93)	3 (96)	3 (100)	0 (100)	0 (100)	0 (100)
	RX-P766	0 (0)	7 (8)	48 (65)	26 (96)	2 (99)	1 (100)	0 (100)	0 (100)	0 (100)
	RX-P770	0 (0)	3 (4)	12 (18)	54 (82)	13 (98)	2 (100)	0 (100)	0 (100)	0 (100)
	RX-P792	2 (2)	8 (12)	35 (54)	34 (94)	3 (98)	2 (100)	0 (100)	0 (100)	0 (100)
	RX-P793	0 (0)	7 (8)	62 (82)	13 (98)	2 (100)	0 (100)	0 (100)	0 (100)	0 (100)
	RX-P808	0 (0)	8 (10)	42 (60)	30 (95)	3 (99)	1 (100)	0 (100)	0 (100)	0 (100)
	Imipenem	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	53 (63)	22 (89)	5 (95)	4 (100)
R-TAZ (≥32 μg/ml; 83)	RX-P763	2 (2)	6 (10)	39 (57)	30 (93)	3 (96)	2 (99)	1 (100)	0 (100)	0 (100)
	RX-P766	0 (0)	8 (10)	51 (71)	20 (95)	2 (98)	2 (100)	0 (100)	0 (100)	0 (100)
	RX-P770	0 (0)	3 (4)	18 (25)	48 (83)	12 (98)	2 (100)	0 (100)	0 (100)	0 (100)
	RX-P792	2 (2)	9 (13)	41 (63)	24 (92)	5 (98)	1 (99)	1 (100)	0 (100)	0 (100)
	RX-P793	0 (0)	11 (13)	57 (82)	13 (98)	1 (99)	1 (100)	0 (100)	0 (100)	0 (100)
	RX-P808	0 (0)	11 (13)	45 (67)	23 (95)	2 (98)	2 (100)	0 (100)	0 (100)	0 (100)
	Ceftazidime	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	37 (45)	24 (73)	22 (100)
R-TZP (≥32 μg/ml; 133)	RX-P763	2 (2)	9 (8)	59 (53)	52 (92)	7 (97)	3 (99)	1 (100)	0 (100)	0 (100)
	RX-P766	0 (0)	11 (8)	77 (66)	40 (96)	3 (98)	2 (100)	0 (100)	0 (100)	0 (100)
	RX-P770	0 (0)	4 (3)	22 (20)	80 (80)	24 (98)	3 (100)	0 (100)	0 (100)	0 (100)
	RX-P792	2 (2)	11 (10)	65 (59)	45 (92)	7 (98)	2 (99)	1 (100)	0 (100)	0 (100)
	RX-P793	0 (0)	15 (11)	88 (77)	28 (98)	1 (99)	1 (100)	0 (100)	0 (100)	0 (100)
	RX-P808	0 (0)	13 (10)	72 (64)	43 (96)	3 (98)	2 (100)	0 (100)	0 (100)	0 (100)
	Piperacillin-tazobactam	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	50 (38)	21 (53)	62 (100)
R-CIPRO (≥4 μg/ml; 64)	RX-P763	1 (2)	4 (8)	22 (42)	31 (91)	4 (97)	2 (100)	0 (100)	0 (100)	0 (100)
	RX-P766	0 (0)	5 (8)	33 (59)	24 (97)	1 (98)	1 (100)	0 (100)	0 (100)	0 (100)
	RX-P770	0 (0)	2 (3)	9 (17)	37 (75)	15 (98)	1 (100)	0 (100)	0 (100)	0 (100)
	RX-P792	1 (2)	6 (11)	24 (48)	28 (92)	4 (98)	1 (100)	0 (100)	0 (100)	0 (100)
	RX-P793	0 (0)	6 (9)	43 (77)	14 (98)	1 (100)	0 (100)	0 (100)	0 (100)	0 (100)
	RX-P808	0 (0)	6 (9)	30 (56)	25 (95)	2 (98)	1 (100)	0 (100)	0 (100)	0 (100)
	Ciprofloxacin	0 (0)	0 (0)	0 (0)	13 (20)	16 (45)	14 (67)	15 (91)	0 (91)	6 (100)
R-TOB (≥16 μg/ml; 42)	RX-P763	0 (0)	2 (5)	17 (46)	19 (93)	3 (100)	0 (100)	0 (100)	0 (100)	0 (100)
	RX-P766	0 (0)	3 (7)	26 (71)	12 (100)	0 (100)	0 (100)	0 (100)	0 (100)	0 (100)
	RX-P770	0 (0)	0 (0)	10 (24)	23 (80)	7 (98)	1 (100)	0 (100)	0 (100)	0 (100)
	RX-P792	0 (0)	5 (12)	18 (56)	18 (100)	0 (100)	0 (100)	0 (100)	0 (100)	0 (100)
	RX-P793	0 (0)	3 (7)	31 (83)	7 (100)	0 (100)	0 (100)	0 (100)	0 (100)	0 (100)
	RX-P808	0 (0)	4 (10)	23 (66)	14 (100)	0 (100)	0 (100)	0 (100)	0 (100)	0 (100)
	Tobramycin	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	5 (12)	8 (32)	6 (46)	22 (100)
MDR (resistance to ≥3 drug classes; 42)	RX-P763	0 (0)	3 (7)	15 (43)	19 (88)	4 (98)	1 (100)	0 (100)	0 (100)	0 (100)
	RX-P766	0 (0)	4 (10)	23 (64)	14 (98)	1 (100)	0 (100)	0 (100)	0 (100)	0 (100)
	RX-P770	0 (0)	1 (2)	6 (17)	26 (79)	9 (100)	0 (100)	0 (100)	0 (100)	0 (100)
	RX-P792	0 (0)	4 (10)	15 (45)	20 (93)	3 (100)	0 (100)	0 (100)	0 (100)	0 (100)
	RX-P793	0 (0)	5 (12)	29 (81)	8 (100)	0 (100)	0 (100)	0 (100)	0 (100)	0 (100)
	RX-P808	0 (0)	5 (12)	20 (60)	15 (95)	2 (100)	0 (100)	0 (100)	0 (100)	0 (100)
	Imipenem	1 (2)	2 (7)	6 (21)	2 (26)	3 (33)	12 (62)	9 (83)	4 (93)	3 (100)
	Piperacillin-Tazobactam	1 (2)	0 (2)	0 (2)	1 (5)	1 (7)	2 (12)	2 (17)	2 (21)	33 (100)
	Ceftazidime	0 (0)	0 (0)	1 (2)	4 (12)	2 (17)	5 (29)	10 (52)	6 (67)	14 (100)
	Ciprofloxacin	0 (0)	0 (0)	6 (14)	7 (31)	9 (52)	8 (71)	9 (93)	0 (93)	3 (100)
	Tobramycin	2 (5)	4 (14)	2 (19)	1 (21)	4 (31)	5 (43)	4 (52)	3 (60)	17 (100)